Lucid Diagnostics (LUCD) Competitors $1.00 +0.04 (+4.17%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LUCD vs. BDSX, SKIN, PROF, SGHT, ZJYL, SONX, BWAY, DRTS, LAKE, and NVROShould you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Biodesix (BDSX), Beauty Health (SKIN), Profound Medical (PROF), Sight Sciences (SGHT), Jin Medical International (ZJYL), Sonendo (SONX), BrainsWay (BWAY), Alpha Tau Medical (DRTS), Lakeland Industries (LAKE), and Nevro (NVRO). Lucid Diagnostics vs. Biodesix Beauty Health Profound Medical Sight Sciences Jin Medical International Sonendo BrainsWay Alpha Tau Medical Lakeland Industries Nevro Lucid Diagnostics (NASDAQ:LUCD) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends. Does the media refer more to LUCD or BDSX? In the previous week, Lucid Diagnostics had 16 more articles in the media than Biodesix. MarketBeat recorded 16 mentions for Lucid Diagnostics and 0 mentions for Biodesix. Lucid Diagnostics' average media sentiment score of 0.21 beat Biodesix's score of -1.00 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Overall Sentiment Lucid Diagnostics Neutral Biodesix Negative Is LUCD or BDSX more profitable? Biodesix has a net margin of -66.84% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat Biodesix's return on equity.Company Net Margins Return on Equity Return on Assets Lucid Diagnostics-1,069.87% N/A -123.54% Biodesix -66.84%-275.79%-43.05% Does the MarketBeat Community believe in LUCD or BDSX? Lucid Diagnostics received 6 more outperform votes than Biodesix when rated by MarketBeat users. However, 74.36% of users gave Biodesix an outperform vote while only 67.31% of users gave Lucid Diagnostics an outperform vote. CompanyUnderperformOutperformLucid DiagnosticsOutperform Votes3567.31% Underperform Votes1732.69% BiodesixOutperform Votes2974.36% Underperform Votes1025.64% Which has stronger valuation & earnings, LUCD or BDSX? Biodesix has higher revenue and earnings than Lucid Diagnostics. Biodesix is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLucid Diagnostics$2.43M24.42-$52.67M-$1.14-0.88Biodesix$49.09M3.53-$52.15M-$0.39-3.05 Do analysts rate LUCD or BDSX? Lucid Diagnostics presently has a consensus target price of $3.69, suggesting a potential upside of 268.75%. Biodesix has a consensus target price of $3.06, suggesting a potential upside of 157.14%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, research analysts clearly believe Lucid Diagnostics is more favorable than Biodesix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Biodesix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of LUCD or BDSX? 74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 8.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 69.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, LUCD or BDSX? Lucid Diagnostics has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. SummaryLucid Diagnostics beats Biodesix on 11 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUCD vs. The Competition Export to ExcelMetricLucid DiagnosticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.72M$4.47B$5.07B$8.89BDividend YieldN/A36.79%4.99%4.07%P/E Ratio-0.8812.2983.5712.93Price / Sales24.4244.861,220.3088.33Price / CashN/A52.2739.4636.25Price / Book-1.195.766.936.25Net Income-$52.67M$13.76M$119.12M$225.93M7 Day Performance-0.99%-1.08%-1.83%-1.32%1 Month Performance19.06%0.58%-3.64%0.60%1 Year Performance-23.08%50.91%31.64%26.23% Lucid Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUCDLucid Diagnostics3.221 of 5 stars$1.00+4.2%$3.69+268.8%-23.1%$56.72M$2.43M-0.8870BDSXBiodesix2.6823 of 5 stars$1.19-4.0%$3.06+157.1%-16.2%$180.38M$49.09M0.00220Negative NewsHigh Trading VolumeSKINBeauty Health2.6897 of 5 stars$1.49-7.5%$2.55+71.1%-36.3%$200.29M$398M0.001,030Analyst RevisionPositive NewsPROFProfound Medical2.4531 of 5 stars$7.69-1.8%$13.75+78.8%-31.2%$193.10M$7.20M0.00150Positive NewsSGHTSight Sciences2.5151 of 5 stars$3.73-1.1%$5.50+47.5%+63.6%$191.35M$81.06M0.00210ZJYLJin Medical InternationalN/A$1.01-16.5%N/A-94.1%$187.55M$19.82M0.00245Positive NewsGap DownHigh Trading VolumeSONXSonendoN/A$2.16+1.4%N/A+815.3%$180.60M$44.40M-4.80250Positive NewsGap UpBWAYBrainsWay3.9884 of 5 stars$9.83+1.7%$13.17+33.9%+103.9%$161.28M$31.78M98.31120Gap UpDRTSAlpha Tau Medical2.4021 of 5 stars$2.30flat$8.00+248.6%-20.7%$160.24MN/A0.0080LAKELakeland Industries4.4003 of 5 stars$21.14-2.0%$26.50+25.4%+44.7%$159.62M$124.69M88.081,750NVRONevro2.8885 of 5 stars$4.23-0.2%$9.10+115.1%-74.5%$158.88M$425.17M0.001,215Analyst UpgradeGap Down Related Companies and Tools Related Companies BDSX Alternatives SKIN Alternatives PROF Alternatives SGHT Alternatives ZJYL Alternatives SONX Alternatives BWAY Alternatives DRTS Alternatives LAKE Alternatives NVRO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LUCD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LUCD Stock Alerts